Welcome to our dedicated page for Kintara Therapeutics SEC filings (Ticker: KTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Kintara Therapeutics releases a new clinical 10-K packed with photodynamic therapy data or files an 8-K about trial-enrollment milestones, investors face pages of oncology jargon and statistical risk factors. Add the flurry of "Kintara Therapeutics insider trading Form 4 transactions" that often follow capital raises, and staying current becomes a full-time job.
Stock Titan solves that problem. Our AI parses every "Kintara Therapeutics quarterly earnings report 10-Q filing", flags REM-001 safety updates, and turns dense footnotes into concise, plain-language briefs. You’ll see "Kintara Therapeutics annual report 10-K simplified" alongside red-line comparisons, plus instant alerts when a director files "Kintara Therapeutics Form 4 insider transactions real-time". Looking for compensation details? The "Kintara Therapeutics proxy statement executive compensation" is broken down so option grants and vesting schedules are clear. Need market-moving news? We tag "Kintara Therapeutics 8-K material events explained" within minutes of hitting EDGAR, complete with context around cash runway or clinical holds. Filing cards labeled "Kintara Therapeutics SEC filings explained simply" keep everything one click away, making "understanding Kintara Therapeutics SEC documents with AI" straightforward.
Use these insights to:
- Track "Kintara Therapeutics executive stock transactions Form 4" before earnings calls
- Run "Kintara Therapeutics earnings report filing analysis" with AI-highlighted R&D trends
- Monitor financing agreements and trial results without wading through appendices
Every submission—from S-3 shelves to Section 16 forms—appears here the moment Kintara uploads it. Coupled with AI-powered summaries, expert annotations, and historical search, you’ll spend less time decoding documents and more time making informed oncology investment decisions.
KP Biotech Group LLC reported beneficial ownership of 447,232 shares of TuHURA Biosciences, Inc. common stock, representing 0.9% of the outstanding class. The filing states these shares confer sole voting and sole dispositive power over all 447,232 shares and that the stake was not acquired to influence control of the issuer. The percent ownership is calculated using an outstanding share count of 50,046,926 shares reported by the issuer. The filing is a Schedule 13G amendment and affirms the position is below the 5% ownership threshold that would trigger more extensive disclosure.
TuHURA Biosciences, Inc. reported that CA Patel F&F Investments, LLC beneficially owned 447,232 shares of the companys common stock as of June 12, 2025. That holding represents 0.9% of the outstanding class, calculated using 50,046,926 shares reported by the issuer as outstanding on August 11, 2025. The filing states the reporting person has sole voting and dispositive power over all 447,232 shares and that the shares were not acquired to influence control of the company.
The Schedule 13G/A provides the filers business address in Tampa, Florida, and is signed by Adam Baals as Manager of CA Patel F&F Investments, LLC on August 14, 2025.
TuHURA Biosciences completed the acquisition of Kineta, Inc. on June 30, 2025 under the Agreement and Plan of Merger dated December 11, 2024, as amended May 5, 2025. The transaction was structured as a two-step series of mergers: Merger Sub I merged into Kineta (the Surviving Entity), which then merged into Merger Sub II, with Merger Sub II surviving.
This Form 8-K/A amends TuHURA’s original June 30, 2025 report to furnish Item 9.01 financial disclosures. The amendment attaches Kineta’s unaudited consolidated financial statements as of March 31, 2025 and December 31, 2024 as Exhibit 99.1 and provides unaudited pro forma condensed combined financial information for TuHURA as Exhibit 99.2, including a pro forma balance sheet and statements of operations on the noted dates and periods. The filing notes substantially the same financial statements were previously included in TuHURA’s Form S-4, declared effective May 14, 2025. The amendment is signed by CFO Dan Dearborn.
FAQ
What is the current stock price of Kintara Therapeutics (KTRA)?
What is the market cap of Kintara Therapeutics (KTRA)?
